

Special Issue

Mesenchymal Stem Cells: Key Players in Cancer Progression

Message from the Guest Editor

Mesenchymal stem cells (MSCs), multipotent cells with a high potential to self-renew and differentiate, have gained attention as important players in modulating cancer progression. Originating from many tissue sources but primarily from bone marrow and the adipose tissue, MSCs home in on the tumor microenvironment and can contribute to metastasis. However, our current understanding of the molecular mechanisms by which MSCs regulate metastasis is still limited. As MSCs are endowed with the capability to differentiate and trans-differentiate, they also contribute to heterogeneity within the stromal compartment, further masking their role within the tumor environment. The advent of new omics technologies to trace cell fate, intercellular interactions, and engineered models of cancer are allowing for increased insight into MSC fate, their signaling potential in transforming tumor and non-tumor cells, and their specific roles in the progression of cancer metastasis. This Special Issue aims to collate research articles or reviews related to MSCs' role in different stages of cancer progression, immunotherapy, and therapeutic approaches targeting MSCs.

Guest Editor

Dr. Kshitiz

Department of Biomedical Engineering, University of Connecticut Health, Farmington, CT, USA

Deadline for manuscript submissions

closed (1 March 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/158015

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)